期刊文献+

Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease 被引量:7

Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease
下载PDF
导出
摘要 AIM To determine if manipulation of dietary advanced glycation end product(AGE), intake affects nonalcoholic fatty liver disease(NAFLD) progression and whether these effects are mediated via RAGE. METHODS Male C57Bl6 mice were fed a high fat, high fructose, high cholesterol(HFHC) diet for 33 wk and compared with animals on normal chow. A third group were given a HFHC diet that was high in AGEs. Another group was given a HFHC diet that was marinated in vinegar to prevent the formation of AGEs. In a second experiment, RAGE KO animals were fed a HFHC diet or a high AGE HFHC diet and compared with wildtype controls. Hepatic biochemistry, histology, picrosirius red morphometry and hepatic mR NA were determined. RESULTS Long-term consumption of the HFHC diet generated significant steatohepatitis and fibrosis after 33 wk. In this model, hepatic 4-hydroxynonenal content(a marker of chronic oxidative stress), hepatocyte ballooning, picrosirius red staining, α-smooth muscle actin and collagen type 1A gene expression were all significantly increased. Increasing the AGE content of the HFHC diet by baking further increased these markers of liver damage, but this was abrogated by pre-marination in acetic acid. In response to the HFHC diet, RAGE-/-animals developed NASH of similar severity to RAGE+/+ animals but were protected from the additional harmful effects of the high AGE containing diet. Studies in isolated Kupffer cells showed that AGEs increase cell proliferation and oxidative stress, providing a likely mechanism through which these compounds contribute to liver injury. CONCLUSION In the HFHC model of NAFLD, manipulation of dietary AGEs modulates liver injury, inflammation, and liver fibrosis via a RAGE dependent pathway. This suggests that pharmacological and dietary strategies targeting the AGE/RAGE pathway could slow the progression of NAFLD. AIM To determine if manipulation of dietary advanced glycation end product(AGE), intake affects nonalcoholic fatty liver disease(NAFLD) progression and whether these effects are mediated via RAGE. METHODS Male C57Bl6 mice were fed a high fat, high fructose, high cholesterol(HFHC) diet for 33 wk and compared with animals on normal chow. A third group were given a HFHC diet that was high in AGEs. Another group was given a HFHC diet that was marinated in vinegar to prevent the formation of AGEs. In a second experiment, RAGE KO animals were fed a HFHC diet or a high AGE HFHC diet and compared with wildtype controls. Hepatic biochemistry, histology, picrosirius red morphometry and hepatic mR NA were determined. RESULTS Long-term consumption of the HFHC diet generated significant steatohepatitis and fibrosis after 33 wk. In this model, hepatic 4-hydroxynonenal content(a marker of chronic oxidative stress), hepatocyte ballooning, picrosirius red staining, α-smooth muscle actin and collagen type 1A gene expression were all significantly increased. Increasing the AGE content of the HFHC diet by baking further increased these markers of liver damage, but this was abrogated by pre-marination in acetic acid. In response to the HFHC diet, RAGE-/-animals developed NASH of similar severity to RAGE+/+ animals but were protected from the additional harmful effects of the high AGE containing diet. Studies in isolated Kupffer cells showed that AGEs increase cell proliferation and oxidative stress, providing a likely mechanism through which these compounds contribute to liver injury. CONCLUSION In the HFHC model of NAFLD, manipulation of dietary AGEs modulates liver injury, inflammation, and liver fibrosis via a RAGE dependent pathway. This suggests that pharmacological and dietary strategies targeting the AGE/RAGE pathway could slow the progression of NAFLD.
出处 《World Journal of Gastroenterology》 SCIE CAS 2016年第35期8026-8040,共15页 世界胃肠病学杂志(英文版)
基金 Supported by National Health and Medical Research Council of Australia NHMRC early career fellowship
关键词 先进 glycation 结束产品 果糖 STEATOHEPATITIS 非酒精的脂肪肝疾病 肝的纤维变性 氧化应力 Advanced glycation end-products Fructose Steatohepatitis Non-alcoholic fatty liver disease Hepatic fibrosis Oxidative stress
  • 相关文献

参考文献2

二级参考文献50

  • 1Schmidt AM,Yan SD,Stern DM.The dark side of glucose.Nat Med 1995; 1:1002-1004.
  • 2Rahbar S,Blumenfeld O,Ranney HM.Studies of an unusual hemoglobin in patients with diabetes mellitus.Biochem Biophys Res Commun 1969; 36:838-843.
  • 3Kirstein M,Brett J,Radoff S,Ogawa S,Stern D,Vlassara H.Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of plateletderived growth factor:role in vascular disease of diabetes and aging.Proc Natl Acad Sci USA 1990; 87:9010-9014.
  • 4Kislinger T,Fu C,Huber B,Qu W,Taguchi A,Du Yan S,Hofmann M,Yan SF,Pischetsrieder M,Stern D,Schmidt AM.N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression.J Biol Chem 1999; 274:31740-31749.
  • 5Horiuchi S,Sakamoto Y,Sakai M.Scavenger receptors for oxidized and glycated proteins.Amino Acids 2003; 25:283-292.
  • 6Iacobini C,Amadio L,Oddi G,Ricci C,Barsotti P,Missori S,Sorcini M,Di Mario U,Pricci F,Pugliese G.Role of galectin-3 in diabetic nephropathy.J Am Soc Nephrol 2003; 14:S264-S270.
  • 7Jerums G,Panagiotopoulos S,Forbes J,Osicka T,Cooper M.Evolving concepts in advanced glycation,diabetic nephropathy,and diabetic vascular disease.Arch Biochem Biophys 2003; 419:55-62.
  • 8Forbes JM,Thallas V,Thomas MC,Founds HW,Burns WC,Jerums G,Cooper ME.The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.FASEB J 2003; 17:1762-1764.
  • 9Bohlender JM,Franke S,Stein G,Wolf G.Advanced glycation end products and the kidney.Am J Physiol Renal Physiol 2005; 289:F645-F659.
  • 10Neuschwander-Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference.Hepatology 2003; 37:1202-1219.

共引文献13

同被引文献29

引证文献7

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部